$DLB Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Dolby Laboratories, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Dolby Laboratories, Inc.. Get notifications about new insider transactions in Dolby Laboratories, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 12 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | M | 37.35 | 29,457 | 1,100,219 | 132,558 | |
May 12 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 95.13 | 900 | 85,620 | 32,895 | 33.8 K to 32.9 K (-2.66 %) |
May 12 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 94.49 | 28,557 | 2,698,457 | 33,795 | 62.4 K to 33.8 K (-45.80 %) |
May 12 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Buy | M | 37.35 | 29,457 | 1,100,219 | 62,352 | 32.9 K to 62.4 K (+89.55 %) |
Apr 14 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | M | 37.35 | 29,457 | 1,100,219 | 162,015 | |
Apr 14 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 101.87 | 1,393 | 141,907 | 32,895 | 34.3 K to 32.9 K (-4.06 %) |
Apr 14 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 101.42 | 28,064 | 2,846,276 | 34,288 | 62.4 K to 34.3 K (-45.01 %) |
Apr 14 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Buy | M | 37.35 | 29,457 | 1,100,219 | 62,352 | 32.9 K to 62.4 K (+89.55 %) |
Mar 17 2021 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Option Exercise | C | 0.00 | 18,500 | 0 | 6,508,117 | |
Mar 17 2021 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Gift | G | 0.00 | 18,500 | 0 | 0 | 18.5 K to 0 (-100.00 %) |
Mar 17 2021 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Buy | C | 0.00 | 18,500 | 0 | 18,500 | 0 to 18.5 K |
Mar 11 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | M | 37.35 | 29,457 | 1,100,219 | 191,472 | |
Mar 11 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 100.10 | 19,163 | 1,918,199 | 32,895 | 52.1 K to 32.9 K (-36.81 %) |
Mar 11 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 99.62 | 10,294 | 1,025,511 | 52,058 | 62.4 K to 52.1 K (-16.51 %) |
Mar 11 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Buy | M | 37.35 | 29,457 | 1,100,219 | 62,352 | 32.9 K to 62.4 K (+89.55 %) |
Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 23,118 | |
Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 100.00 | 13,000 | 1,300,000 | 50,010 | 63 K to 50 K (-20.63 %) |
Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
Feb 26 2021 | DLB | Dolby Laboratories ... | Rollins Emily | Director | Grant | A | 0.00 | 2,462 | 0 | 2,462 | 0 to 2.5 K |
Feb 24 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 68.40 | 10,229 | 699,664 | 29,946 | |
Feb 24 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 95.09 | 10,229 | 972,646 | 32,956 | 43.2 K to 33 K (-23.69 %) |
Feb 24 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 68.40 | 10,229 | 699,664 | 43,185 | 33 K to 43.2 K (+31.04 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 68.40 | 2,100 | 143,640 | 40,175 | |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 62.43 | 7,813 | 487,766 | 44,271 | |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 64.60 | 2,250 | 145,350 | 16,500 | |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 94.13 | 2,306 | 217,055 | 32,956 | 35.3 K to 33 K (-6.54 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 94.01 | 2,100 | 197,413 | 35,262 | 37.4 K to 35.3 K (-5.62 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 68.40 | 2,100 | 143,640 | 37,362 | 35.3 K to 37.4 K (+5.96 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 94.11 | 7,813 | 735,251 | 35,262 | 43.1 K to 35.3 K (-18.14 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 62.43 | 7,813 | 487,766 | 43,075 | 35.3 K to 43.1 K (+22.16 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 94.00 | 2,250 | 211,500 | 35,262 | 37.5 K to 35.3 K (-6.00 %) |
Feb 22 2021 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 64.60 | 2,250 | 145,350 | 37,512 | 35.3 K to 37.5 K (+6.38 %) |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 36,118 | |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 95.00 | 13,000 | 1,235,000 | 50,010 | 63 K to 50 K (-20.63 %) |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 36,118 | |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 95.00 | 13,000 | 1,235,000 | 50,010 | 63 K to 50 K (-20.63 %) |
Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
Feb 09 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | M | 37.35 | 29,457 | 1,100,219 | 220,929 | |
Feb 09 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 91.86 | 5,357 | 492,107 | 32,895 | 38.3 K to 32.9 K (-14.00 %) |
Feb 09 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 91.95 | 29,457 | 2,708,483 | 38,252 | 67.7 K to 38.3 K (-43.51 %) |
Feb 09 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Buy | M | 37.35 | 29,457 | 1,100,219 | 67,709 | 38.3 K to 67.7 K (+77.01 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 23,118 | 1,051,869 | 0 | |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 2,882 | 131,131 | 49,118 | |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 496 | 45,746 | 50,010 | 50.5 K to 50 K (-0.98 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.58 | 22,622 | 2,071,718 | 50,506 | 73.1 K to 50.5 K (-30.93 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 23,118 | 1,051,869 | 73,128 | 50 K to 73.1 K (+46.23 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 175 | 16,140 | 50,010 | 50.2 K to 50 K (-0.35 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.48 | 2,707 | 247,635 | 50,185 | 52.9 K to 50.2 K (-5.12 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 2,882 | 131,131 | 52,892 | 50 K to 52.9 K (+5.76 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 227 | 20,936 | 50,010 | 50.2 K to 50 K (-0.45 %) |
Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.68 | 1,436 | 131,649 | 50,237 | 51.7 K to 50.2 K (-2.78 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | TEVANIAN AVADIS | Director | Sell | S | 90.00 | 1,814 | 163,260 | 50,561 | 52.4 K to 50.6 K (-3.46 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | TEVANIAN AVADIS | Director | Grant | A | 0.00 | 2,661 | 0 | 2,661 | 0 to 2.7 K |
Feb 04 2021 | DLB | Dolby Laboratories ... | Sud Anjali | Director | Grant | A | 0.00 | 2,661 | 0 | 8,873 | 6.2 K to 8.9 K (+42.84 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | SIBONI ROGER S | Director | Grant | A | 0.00 | 2,661 | 0 | 34,771 | 32.1 K to 34.8 K (+8.29 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | Segars Simon | Director | Grant | A | 0.00 | 2,661 | 0 | 33,571 | 30.9 K to 33.6 K (+8.61 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | Nicholson Ryan | VP, Corporate Contr ... | Sell | S | 91.01 | 2,237 | 203,583 | 10,223 | 12.5 K to 10.2 K (-17.95 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | JASPER N WILLIAM JR | Director | Sell | S | 90.33 | 3,627 | 327,643 | 7,000 | 10.6 K to 7 K (-34.13 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | GOTCHER PETER C | Director | Grant | A | 0.00 | 2,661 | 0 | 40,929 | 38.3 K to 40.9 K (+6.95 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | Dolby David | Director | Grant | A | 0.00 | 2,661 | 0 | 76,639 | 74 K to 76.6 K (+3.60 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Option Exercise | M | 42.98 | 30,000 | 1,289,400 | 60,918 | |
Feb 04 2021 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Sell | S | 90.82 | 30,000 | 2,724,669 | 105,598 | 135.6 K to 105.6 K (-22.12 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Buy | M | 42.98 | 30,000 | 1,289,400 | 135,598 | 105.6 K to 135.6 K (+28.41 %) |
Feb 04 2021 | DLB | Dolby Laboratories ... | Chau Micheline | Director | Grant | A | 0.00 | 2,661 | 0 | 60,803 | 58.1 K to 60.8 K (+4.58 %) |
Jan 19 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | G | 92.08 | 91,597 | 8,434,252 | 91,597 | |
Jan 19 2021 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | G | 92.08 | 91,597 | 8,434,252 | 0 | |
Dec 23 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | M | 45.50 | 21,850 | 994,175 | 0 | |
Dec 23 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 94.00 | 21,850 | 2,053,900 | 32,376 | 54.2 K to 32.4 K (-40.29 %) |
Dec 23 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Buy | M | 45.50 | 21,850 | 994,175 | 54,226 | 32.4 K to 54.2 K (+67.49 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 92.07 | 5,168 | 475,830 | 38,252 | 43.4 K to 38.3 K (-11.90 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Payment of Exercise | F | 91.03 | 5,082 | 462,614 | 106,414 | 111.5 K to 106.4 K (-4.56 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.96 | 1,638 | 150,629 | 51,673 | 53.3 K to 51.7 K (-3.07 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 91.03 | 1,612 | 146,740 | 53,311 | 54.9 K to 53.3 K (-2.94 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Payment of Exercise | F | 91.03 | 1,116 | 101,589 | 35,262 | 36.4 K to 35.3 K (-3.07 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Nicholson Ryan | VP, Corporate Contr ... | Payment of Exercise | F | 91.03 | 217 | 19,754 | 12,460 | 12.7 K to 12.5 K (-1.71 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Forshay Steven E | SVP, Advanced Techn ... | Payment of Exercise | F | 91.03 | 1,116 | 101,589 | 57,846 | 59 K to 57.8 K (-1.89 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Payment of Exercise | F | 91.03 | 1,612 | 146,740 | 105,598 | 107.2 K to 105.6 K (-1.50 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 92.30 | 1,575 | 145,373 | 32,376 | 34 K to 32.4 K (-4.64 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 91.65 | 1,575 | 144,349 | 33,951 | 35.5 K to 34 K (-4.43 %) |
Dec 21 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Payment of Exercise | F | 91.03 | 1,550 | 141,097 | 35,526 | 37.1 K to 35.5 K (-4.18 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | A | 92.08 | 91,597 | 8,434,252 | 91,597 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Option Exercise | A | 0.00 | 21,394 | 0 | 21,394 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Payment of Exercise | F | 92.08 | 5,268 | 485,077 | 116,664 | 121.9 K to 116.7 K (-4.32 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 91.61 | 1,771 | 162,239 | 32,895 | 34.7 K to 32.9 K (-5.11 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Sell | S | 90.60 | 9,768 | 885,024 | 34,666 | 44.4 K to 34.7 K (-21.98 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Grant | A | 0.00 | 42,789 | 0 | 127,289 | 84.5 K to 127.3 K (+50.64 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | YEAMAN KEVIN J | President and CEO | Payment of Exercise | F | 90.86 | 11,349 | 1,031,170 | 84,500 | 95.8 K to 84.5 K (-11.84 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 92.08 | 30,553 | 2,813,320 | 30,553 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 0.00 | 7,136 | 0 | 7,136 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.66 | 337 | 30,888 | 54,923 | 55.3 K to 54.9 K (-0.61 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 90.62 | 3,065 | 277,748 | 55,260 | 58.3 K to 55.3 K (-5.26 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 92.08 | 1,637 | 150,735 | 58,325 | 60 K to 58.3 K (-2.73 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 14,272 | 0 | 59,962 | 45.7 K to 60 K (+31.24 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 90.86 | 3,348 | 304,199 | 45,690 | 49 K to 45.7 K (-6.83 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | A | 92.08 | 27,253 | 2,509,456 | 27,253 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | A | 0.00 | 6,365 | 0 | 6,365 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Payment of Exercise | F | 92.08 | 1,153 | 106,168 | 36,378 | 37.5 K to 36.4 K (-3.07 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Grant | A | 0.00 | 12,731 | 0 | 37,531 | 24.8 K to 37.5 K (+51.33 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Nicholson Ryan | VP, Corporate Contr ... | Payment of Exercise | F | 92.08 | 195 | 17,956 | 12,677 | 12.9 K to 12.7 K (-1.51 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Nicholson Ryan | VP, Corporate Contr ... | Grant | A | 0.00 | 4,500 | 0 | 12,872 | 8.4 K to 12.9 K (+53.75 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Nicholson Ryan | VP, Corporate Contr ... | Payment of Exercise | F | 90.86 | 444 | 40,342 | 8,372 | 8.8 K to 8.4 K (-5.04 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Forshay Steven E | SVP, Advanced Techn ... | Option Exercise | M | 45.50 | 834 | 37,947 | 0 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Forshay Steven E | SVP, Advanced Techn ... | Sell | S | 92.00 | 834 | 76,728 | 58,962 | 59.8 K to 59 K (-1.39 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Forshay Steven E | SVP, Advanced Techn ... | Buy | M | 45.50 | 834 | 37,947 | 59,796 | 59 K to 59.8 K (+1.41 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Forshay Steven E | SVP, Advanced Techn ... | Payment of Exercise | F | 90.86 | 2,356 | 214,066 | 58,962 | 61.3 K to 59 K (-3.84 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Option Exercise | A | 92.08 | 30,553 | 2,813,320 | 30,553 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Option Exercise | A | 0.00 | 7,136 | 0 | 7,136 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Payment of Exercise | F | 92.08 | 1,637 | 150,735 | 107,210 | 108.8 K to 107.2 K (-1.50 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Grant | A | 0.00 | 14,272 | 0 | 108,847 | 94.6 K to 108.8 K (+15.09 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Payment of Exercise | F | 90.86 | 3,472 | 315,466 | 94,575 | 98 K to 94.6 K (-3.54 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | M | 45.50 | 959 | 43,635 | 0 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | A | 92.08 | 28,903 | 2,661,388 | 28,903 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | A | 0.00 | 6,750 | 0 | 6,750 | |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 91.31 | 526 | 48,031 | 37,076 | 37.6 K to 37.1 K (-1.40 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 91.00 | 433 | 39,403 | 37,602 | 38 K to 37.6 K (-1.14 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Buy | M | 45.50 | 959 | 43,635 | 38,035 | 37.1 K to 38 K (+2.59 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Payment of Exercise | F | 92.08 | 1,550 | 142,724 | 37,076 | 38.6 K to 37.1 K (-4.01 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 91.92 | 702 | 64,530 | 38,626 | 39.3 K to 38.6 K (-1.78 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 90.90 | 2,385 | 216,808 | 39,328 | 41.7 K to 39.3 K (-5.72 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Grant | A | 0.00 | 13,501 | 0 | 41,713 | 28.2 K to 41.7 K (+47.86 %) |
Dec 17 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Payment of Exercise | F | 90.86 | 3,038 | 276,033 | 28,212 | 31.3 K to 28.2 K (-9.72 %) |
Nov 25 2020 | DLB | Dolby Laboratories ... | Segars Simon | Director | Gift | G | 0.00 | 1,200 | 0 | 30,910 | 32.1 K to 30.9 K (-3.74 %) |
Nov 25 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 64.60 | 5,191 | 335,339 | 18,750 | |
Nov 25 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 89.69 | 5,191 | 465,567 | 24,800 | 30 K to 24.8 K (-17.31 %) |
Nov 25 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 64.60 | 5,191 | 335,339 | 29,991 | 24.8 K to 30 K (+20.93 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 62.43 | 26,041 | 1,625,740 | 52,084 | |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Option Exercise | M | 64.60 | 2,309 | 149,161 | 23,941 | |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 89.87 | 2,862 | 257,197 | 24,800 | 27.7 K to 24.8 K (-10.35 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 89.35 | 26,041 | 2,326,813 | 27,662 | 53.7 K to 27.7 K (-48.49 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 62.43 | 26,041 | 1,625,740 | 53,703 | 27.7 K to 53.7 K (+94.14 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Sell | S | 89.80 | 2,309 | 207,351 | 27,662 | 30 K to 27.7 K (-7.70 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Pendleton Todd | SVP, Chief Marketin ... | Buy | M | 64.60 | 2,309 | 149,161 | 29,971 | 27.7 K to 30 K (+8.35 %) |
Nov 20 2020 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Option Exercise | G | 0.00 | 3,000,000 | 0 | 3,000,000 | |
Nov 20 2020 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Option Exercise | G | 0.00 | 3,000,000 | 0 | 6,526,617 | |
Nov 20 2020 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Option Exercise | J | 0.00 | 1,800,000 | 0 | 9,526,617 | |
Nov 20 2020 | DLB | Dolby Laboratories ... | Dolby Dagmar | 10% Owner | Option Exercise | J | 0.00 | 1,300,000 | 0 | 7,726,617 | |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | M | 45.50 | 23,000 | 1,046,500 | 23,000 | |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Option Exercise | M | 42.98 | 68,117 | 2,927,669 | 0 | |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 87.14 | 23,000 | 2,004,275 | 31,250 | 54.3 K to 31.3 K (-42.40 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Buy | M | 45.50 | 23,000 | 1,046,500 | 54,250 | 31.3 K to 54.3 K (+73.60 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 87.61 | 100 | 8,761 | 31,250 | 31.4 K to 31.3 K (-0.32 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Sell | S | 87.22 | 68,017 | 5,932,660 | 31,350 | 99.4 K to 31.4 K (-68.45 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | Baker Giles | SVP, Consumer Enter ... | Buy | M | 42.98 | 68,117 | 2,927,669 | 99,367 | 31.3 K to 99.4 K (+217.97 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Option Exercise | M | 42.98 | 7,000 | 300,860 | 90,918 | |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Option Exercise | M | 37.35 | 23,652 | 883,402 | 0 | |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Sell | S | 89.11 | 7,000 | 623,767 | 98,047 | 105 K to 98 K (-6.66 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Buy | M | 42.98 | 7,000 | 300,860 | 105,047 | 98 K to 105 K (+7.14 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Sell | S | 89.45 | 23,652 | 2,115,712 | 98,047 | 121.7 K to 98 K (-19.43 %) |
Nov 18 2020 | DLB | Dolby Laboratories ... | CHEW LEWIS | EVP & Chief Financi ... | Buy | M | 37.35 | 23,652 | 883,402 | 121,699 | 98 K to 121.7 K (+24.12 %) |